Live Markets
Tuesday, July 28, 2026·George Town, KY·29°·Partly Cloudy
Markets Open · NYSE·Newsletter·Masthead·
VOL. XII · NO. 117Established MMXIV · George Town, Grand CaymanAtlantic Edition · $4.50

The Cayman Journal

Finance · Business · Technology · Caribbean & Global Affairs
Markets · Healthcare

Edwards Lifesciences Corporation (EW)

NYQ · Medical Devices

$83.68+0.64 (+0.77%)Quote refreshed

Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires

Market Cap
$48.18B
P/E (TTM)
49.51
EPS
$1.69
Div Yield
—
52W Range
$72.30–$96.29
Beta
0.85

Company overview

Next earnings: 2026-07-23

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.

Peers in Medical Devices

All in industry →

Recent press releases

April 2026

3 months ago8-KHealthcare

EW Raises 2026 Guidance After Strong Q1 Earnings

EWEdwards Lifesciences Corp

# 🧾 What This Document Is This is an **earnings release** – a quarterly report card for investors. Edwards Lifesciences is telling the world how much money it made, spent, and earned from January to March 2026. It’s also updating its predictions for the rest of the year. 👉 **Key takeaway:** The co

Read summaryView on SEC EDGAR
1 recent filing shown in the timeline above. View all SEC filings →

Edwards Lifesciences Corporation has no reported insider trades in the last 90 days.

Institutional holders

All holders →
As of 2025-12-31 · prior 2025-09-30
70,079,435 sh-0.4%
6,502,638 sh+159.3%
9,427,396 sh+30.6%
FMR LLC$1.41B
16,582,547 sh+13.7%
26,024,852 sh+3.9%
52,461,915 sh-3.4%
21,793,949 sh+4.8%
5,925,627 sh+66.1%

People at Edwards Lifesciences Corporation

All people →

Quarterly financials

Full financials →
Revenue trend
03/25
$341.8M
NI $358.0M
06/25
$169.0M
NI $333.2M
09/25
$1.55B
NI $291.1M
RevenueNI = Net Income
EPS trend (diluted)
Latest: $0.50
Prior: $0.56
Revenue sparkline
EW (NYQ) Stock Quote, Press Releases & SEC Filings | Cayman Journal | Cayman Journal